Stewart Katz, MD
Interventional Cardiology · Tulsa, OKNPI 1659452324
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 750 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,470 and has fallen 84.4% since, to $541 in 2024.
Across 750 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Johnson & Johnson$1K
- AstraZeneca$1K
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$988
- Esperion Therapeutics, Inc.$904
- plus $6K from 29 others
Across 4 payments — averaging $2048.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$8K
What the payments were for
- Food & beverage$13,418100%
- Education$530%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 85 | $1,668 |
| Johnson & Johnson | 82 | $1,437 |
| AstraZeneca | 54 | $1,315 |
| Novartis | 85 | $1,267 |
| E.r. Squibb & Sons, L.L.C. | 53 | $988 |
| Esperion Therapeutics, Inc. | 46 | $904 |
| Merck | 36 | $832 |
| Bayer | 30 | $670 |
| Sanofi-aventis U.S. LLC | 25 | $530 |
| Boehringer Ingelheim | 20 | $424 |
| Pfizer | 29 | $422 |
| Amarin Pharma, Inc. | 26 | $403 |
| Kowa Pharmaceuticals America, Inc. | 41 | $392 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $364 |
| Arbor Pharmaceuticals, Inc. | 23 | $335 |
| Philips North America LLC | 46 | $317 |
| Novo Nordisk | 7 | $314 |
| Lundbeck LLC | 9 | $175 |
| Bardy Diagnostics, Inc. | 5 | $144 |
| Azurity Pharmaceuticals, Inc. | 4 | $77 |
| Abbott | 3 | $52 |
| Kestra Medical Technology Services, Inc. | 2 | $42 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $42 |
| Medtronic | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Bard Peripheral Vascular, Inc. | 1 | $38 |
| Silk Road Medical, Inc. | 1 | $37 |
| Althera Pharmaceuticals LLC | 4 | $31 |
| Medicure Pharma Inc. | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| Amryt Pharma Holdings Ltd | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Edwards Lifesciences | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,471 in reported general payments places this provider in the 70th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 156 | $128,625 |
| XareltoRivaroxaban | 113 | $118,437 |
| EntrestoSacubitril/Valsartan | 74 | $80,313 |
| Repatha SureclickEvolocumab | 69 | $64,886 |
| FarxigaDapagliflozin Propanediol | 47 | $38,071 |
| KerendiaFinerenone | 23 | $25,077 |
| Praluent PenAlirocumab | 15 | $13,056 |
| JardianceEmpagliflozin | 13 | $12,513 |
| Eplerenone | 155 | $11,940 |
| VascepaIcosapent Ethyl | 32 | $11,465 |
| BrilintaTicagrelor | 28 | $10,280 |
| LivaloPitavastatin Calcium | 11 | $9,795 |
| Rosuvastatin Calcium | 121 | $5,901 |
| Nebivolol Hcl | 85 | $4,778 |
| ClopidogrelClopidogrel Bisulfate | 254 | $3,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $422 | $128,625156 claims |
| Johnson & JohnsonXarelto | $1,437 | $118,437113 claims |
| NovartisEntresto | $1,267 | $80,31374 claims |
| AstraZenecaFarxiga, Brilinta | $1,315 | $48,35175 claims |
| BayerKerendia | $670 | $25,07723 claims |
| Boehringer IngelheimJardiance | $424 | $12,51313 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $392 | $9,79511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Tulsa
- Kamran MuhammadTulsa$1.4M
- Stanley ZimmermanTulsa$93K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
- Tom HuTulsa$57K
- Eugene IchinoseTulsa$49K
- Poorya FazelTulsa$29K
- Tucker HarrisonTulsa$19K
- Andrew KurklinskyTulsa$15K
- Arash KarnamaTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.